Zion Market Research has published a new report titled “Bile Duct Cancer Drug Market by Type (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin, and Others) and by Application (Hospitals, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”. According to the report, the global bile duct cancer drug market was valued at approximately USD 168 million in 2017 and is expected to generate revenue of around USD 262 million by 2024, at a CAGR of around 6.6% between 2018 and 2024.
Bile duct connects the liver to the gallbladder and carries the fluid called bile, which is synthesized by the liver and stored in the gallbladder. The key function of bile is to break fats and help in digestion. The specific cause of bile duct cancer is unknown, but various factors responsible for bile duct cancer are abnormalities in the bile duct, liver inflammation, exposure to harmful chemicals and toxins, etc. The main symptoms of bile duct cancer include weight loss, discoloration of stool and urine, jaundice, loss of appetite, abdominal pain, etc. Some drugs used to treat bile duct cancer include cisplatin (Platinol), fluorouracil (5-FU, Adrucil), oxaliplatin (Eloxatin), capecitabine (Xeloda), gemcitabine (Gemzar), etc.
The major growth driver of the global bile duct cancer drug market is the increase in the prevalence of bile duct cancer patients across the globe. The increasing prevalence of bile duct cancer is fuelling the demand for treatment. The technological advancement has increased over the period which has led to the development of treatment options. Furthermore, the increase in healthcare expenditure due to increased awareness among people is also expected to promote the growth of bile duct cancer drug market.
The bile duct cancer drug market is classified into type and application. By type, this market is divided into 5-fluorouracil (5-FU), gemcitabine, cisplatin, capecitabine, oxaliplatin, and others. The 5-fluorouracil segment is anticipated to hold the largest market share over the forecast years. By application, this market is segmented into hospitals, clinics, and others. Hospitals are expected to hold the largest market share in the forecast time period.
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa comprise the regional segment of the global bile duct cancer drug market. The Asia Pacific bile duct cancer drug market is expected to grow at the highest CAGR over the forecast time period, owing to increasing cases of risk of liver fluke infections and growing awareness programs, conferences, and funding activities. North America is projected to lead the global bile duct cancer drug market. Increased prevalence of bile duct cancer, a large number of ongoing research activities, the quicker and easy product approval process, rising number of awareness programs, and growing government and public-private investments in this region are the key factors driving this regional market.
Some key players of the bile duct cancer drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., and Celgene Corporation, among others.
This report segments the global bile duct cancer drug market into:
Global Bile Duct Cancer Drug Market: By Product
Global Bile Duct Cancer Drug Market: By Application
Global Bile Duct Cancer Drug Market: By Region
You can Buy This Report from Here @ https://www.zionmarketresearch.com/buynow/su/bile-duct-cancer-drug-market/news